Jonathan Alicea

An observational cross-sectional study finds that patients suffering from such inflammatory conditions had a higher average number of missing teeth compared to the control group.

A higher proportion of patients with immune-mediated diseases experienced ≥1 thromboembolic events at baseline compared to those without an IMD.

The therapy was generally well-tolerated and offered substantial pain relief in patients.

“The sustained benefits for patients with active psoriatic arthritis across multiple domains indicate that guselkumab may offer a novel mechanism by which to provide extended improvements in the diverse manifestations of psoriatic arthritis,” Laura Coates, PhD, and team concluded.

A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.

A majority of studies reported a worsening of disease activity post-delivery.

Patients with psoriasis who either remained on Humira or switched to a biosimilar showed similar retention rates and efficacy/safety data.

A meta-analysis notes that relative risk for stroke was high for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and gout.

A majority of patients with active psoriatic arthritis achieved and maintained skin clearance, joint symptom relief through year 2 of treatment.

Children who received methylprednisolone added to intravenous immunoglobulins experienced lower risk of treatment failure and use of second-line therapy

Increasing dosage of mometasone is associated with elevated risk of osteoporosis and major osteoporotic fractures.

The IL-23 inhibitor is shown to improve disease activity across joint and skin symptoms.

A pediatric dermatologist discusses her experience managing and treating psoriasis in children.

The assessed sickle cell population had high rates of low vitamin D levels and bone marrow density, but there was no strong correlation between both conditions.

This approval makes the drug the first of its kind to treat polyarticular juvenile idiopathic arthritis and psoriatic arthritis in a pediatric population.

An expert discusses the difficulties in diagnosing and managing myositis, as well as how the COVID-19 pandemic has affected clinical care.

Care of rheumatic patients must factor in cradiovascular risk and conditions.

The recently published American College of Rheumatology guidelines on reproductive health is a great resource for rheumatologists.

An expert discusses the role of the rheumatologist in managing cardiovascular risk factors as well as current gaps in the field.

MIS-C is a condition recently recognized in children with COVID-19.

Rheumatologists and OB-GYNs must communicate openly with each other and to patients with rheumatic diseases who are considering pregnancy.

In the MONARCH OLE study, more than 50% of patients with rheumatoid arthritis who had low or inadequate response to adalimumab and switched to sarilumab experienced an improvement in disease activity.

Patient assessments measured fatigue, disease activity, global spinal pain, and spinal pain at night.

COVID-19 is associated with its own cytokine storm syndrome.

These findings suggest the possibility of a common underlying disease process between the two pathologies.

Report shows that sarilumab may be better at controlling severe and refractory pain in rheumatoid arthritis patients than adalimumab.

An expert discusses the risks that rheumatic diseases pose for pregnancies as well as the conversations rheumatologists need to have with their patients.

A post-hoc analysis of 3 randomized controlled trials reports on the associations between the IL-6 inhibitor and unacceptable or refractory pain.

Other measures, like home oxygen dependency, all-cause mortality, and hospitalization for respiratory failures rates, had no apparent association with RF and/or ACPA status

According to a poster presented at CCR East 2020, patients <60 and ≥60 years old achieved minimal disease activity and cDAPSA low disease or remission.